Novel pharmacological inhibitors demonstrate the role of the tyrosine kinase Pyk2 in adhesion and aggregation of human platelets

Summary

Pyk2 is a Ca²⁺-regulated kinase predominantly expressed in neuronal and in haematopoietic cells. Previous studies on Pyk2-null mice have demonstrated that Pyk2 plays a crucial role in platelet activation and thrombus formation, thus representing a possible target for antithrombotic therapy. Very limited information is available about the role of Pyk2 in human platelets, mainly because of the lack of specific pharmacological inhibitors. In this work, we have tested two novel Pyk2 inhibitors, PF-4594755 and PF-4520440, to validate their specificity and to investigate their ability to modulate platelet activation. Both molecules were able to efficiently block Pyk2 activity in human and mouse platelets stimulated with thrombin or with the Ca²⁺-ionophore. In wild-type murine platelets, PF-4594755 and PF-4520440 reduced thrombin-induced aggregation to the level observed in Pyk2 knockout platelets, but did not affect aggregation induced by GPVI stimulation. Importantly, neither compounds affected the residual thrombin-induced aggregation of Pyk2-null platelets, thus excluding possible off-target effects. In human platelets, PF-4594755 and PF-4520440 significantly reduced aggregation stimulated by thrombin, but not by the GPVI agonist convulxin. Both inhibitors reduced platelet adhesion on fibrinogen and prevented Akt phosphorylation in adherent cells, indicating that Pyk2 regulates PI3K and cell spreading downstream of integrins in human platelets. Finally, the Pyk2 inhibitors significantly inhibited thrombus formation upon blood perfusion on immobilized collagen under arterial flow rate. These results demonstrate that PF-4594755 and PF-4520440 are specific inhibitors of Pyk2 in intact platelets and allowed to reliably document that this kinase plays a relevant role in human platelet activation.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Pyk2 - platelet adhesion - platelet aggregation - PI3K - pharmacological inhibitors

• References

• 1 McFadyen JD, Jackson SP. Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemost 2013; 110: 859-867.
• 2 Mahoney EM, Wang K, Cohen DJ. et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circulation Cardiov-asc Qual Outcomes 2008; 01: 38-45.
• 3 Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Ar-terioscl Thromb Vasc Biol 2008; 28: s25-32.
• 4 Guidetti GF, Canobbio I, Torti M. PI3K/Akt in platelet integrin signaling and implications in thrombosis. Advan Biol Regul 2015; 59: 36-52.
• 5 Lipinski CA, Loftus JC. Targeting Pyk2 for therapeutic intervention. Exp Opin Therap Targ 2010; 14: 95-108.
• 6 Sasaki H, Nagura K, Ishino M. et al. Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem 1995; 270: 21206-21219.
• 7 Li J, Avraham H, Rogers RA. et al. Characterization of RAFTK, a novel focal adhesion kinase, and its integrin-dependent phosphorylation and activation in megakaryocytes. Blood 1996; 88: 417-428.
• 8 Ostergaard HL, Lysechko TL. Focal adhesion kinase-related protein tyrosine ki-nase Pyk2 in T-cell activation and function. Immunol Res 2005; 31: 267-282.
• 9 Kohno T, Matsuda E, Sasaki H. et al. Protein-tyrosine kinase CAKbeta/PYK2 is activated by binding Ca2+/calmodulin to FERM F2 alpha2 helix and thus forming its dimer. Biochem J 2008; 410: 513-523.
• 10 Park SY, Avraham HK, Avraham S. RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner. J Biol Chem 2004; 279: 33315-33322.
• 11 Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010; 123: 1007-1013.
• 12 Canobbio I, Cipolla L, Consonni A. et al. Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca(2+)-dependent tyro-sine kinase Pyk2. Blood 2013; 121: 648-657.
• 13 Canobbio I, Cipolla L, Guidetti GF. et al. The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphory-lation in thrombin-stimulated platelets. Biochem J 2015; 469: 199-210.
• 14 Consonni A, Cipolla L, Guidetti G. et al. Role and regulation of phosphatidyli-nositol 3-kinase beta in platelet integrin alpha2beta1 signaling. Blood 2012; 119: 847-856.
• 15 Cipolla L, Consonni A, Guidetti G. et al. The proline-rich tyrosine kinase Pyk2 regulates platelet integrin alphaIIbbeta3 outside-in signaling. J Thromb Hae-most 2013; 11: 345-356.
• 16 Bhattacharya SK, Aspnes GE, Bagley SW. et al. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors. Bioorgan Med Chem Lett 2012; 22: 7523-7529.
• 17 Matsui A, Okigaki M, Amano K. et al. Central role of calcium-dependent tyro-sine kinase PYK2 in endothelial nitric oxide synthase-mediated angiogenic response and vascular function. Circulation 2007; 116: 1041-1051.
• 18 Canobbio I, Catricala S, Di Pasqua LG. et al. Immobilized amyloid Abeta pep-tides support platelet adhesion and activation. FEBS Lett 2013; 587: 2606-2611.
• 19 Manganaro D, Consonni A, Guidetti GF. et al. Activation of phosphatidylinositol 3-kinase beta by the platelet collagen receptors integrin alpha2beta1 and GPVI: The role of Pyk2 and c-Cbl. Biochim Biophys Acta 2015; 1853: 1879-1888.
• 20 Guidetti GF, Consonni A, Cipolla L. et al. Nanoparticles induce platelet activation in vitro through stimulation of canonical signalling pathways. Nano-medicine 2012; 08: 1329-1336.
• 21 Guidetti GF, Bernardi B, Consonni A. et al. Integrin alpha2beta1 induces phos-phorylation-dependent and phosphorylation-independent activation of phosp-holipase Cgamma2 in platelets: role of Src kinase and Rac GTPase. J Thromb Haemost 2009; 07: 1200-1206.
• 22 Bernardi B, Guidetti GF, Campus F. et al. The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2beta1 and integrin alphaIIbbeta3. Blood 2006; 107: 2728-2735.
• 23 Kim S, Cipolla L, Guidetti G. et al. Distinct role of Pyk2 in mediating thrombox-ane generation downstream of both G12/13 and integrin alphaIIbbeta3 in platelets. J Biol Chem 2013; 288: 18194-18203.
• 24 Carrim N, Walsh TG, Consonni A. et al. Role of focal adhesion tyrosine kinases in GPVI-dependent platelet activation and reactive oxygen species formation. PloS one 2014; 09: e113679.
• 25 Buckbinder L, Crawford DT, Qi H. et al. Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc Natl Acad Sci USA 2007; 104: 10619-10624.
• 26 Shen CJ, Raghavan S, Xu Z. et al. Decreased cell adhesion promotes angiogen-esis in a Pyk2-dependent manner. Exp Cell Res 2011; 317: 1860-1871.
• 27 Bonnette PC, Robinson BS, Silva JC. et al. Phosphoproteomic characterization of PYK2 signaling pathways involved in osteogenesis. J Proteomics 2010; 73: 1306-1320.
• 28 Bhattachariya A, Turczynska KM, Grossi M. et al. PYK2 selectively mediates signals for growth versus differentiation in response to stretch of spontaneously active vascular smooth muscle. Physiol Rep 2014; 2.
• 29 Jones ML, Shawe-Taylor AJ, Williams CM. et al. Characterization of a novel focal adhesion kinase inhibitor in human platelets. Biochem Biophys Res Com-mun 2009; 389: 198-203.